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ABSTRACT: Nearly half a century ago anticoagulant rodenticides changed the nature of rodent control. Warfarin, and 
succeeding first-generation compounds, provided effective and increasingly safe baits for reducing commensal rodent popula-
tions. Environmental deficiencies were overridden by these “miracle” chemicals, but excessive and irresponsible use selected 
for resistant populations. Second-generation compounds with a single-feeding characteristic have controlled such resistant 
populations, at least initially. But use extensions to crop and field areas have been held back by registration requirements, costs, 
and concerns over local effects on predators. New compounds, formulations, and applications in the near future are likely to be 
quite limited. 
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INTRODUCTION 
Compound 42, the first anticoagulant rodenticide, was 
field tested in the U.S. in the late 1940s. It was introduced 
commercially in the early 1950s as Warfarin (after the Wis-
consin Alumni Research Foundation, which had sponsored 
the development research). Overnight it became the “miracle” 
rodenticide because of its relative safety (multiple-dose re-
quirement), ease of use (grain baits and “toss” packs), and 
efficacy (lack of bait shyness). 
In the course of time other coumarin and the similar 
indandione molecules were synthesized. The half-dozen 
technical products were the basis for a flourishing rodenticide 
market. These compounds (including chlorophacinine, 
coumafuryl, diphacinone, isovaleryl indandione, pindone) 
later were to be designated as first-generation anticoagulants. 
Less was heard of Compound 1080, zinc phosphide, arsenic, 
ANTU, strychnine, and thallium, though “old timers” con-
tinued to have their favorite (and “secret”) formulas using 
these compounds; and such products did not disappear totally 
from the OTC market. 
Despite the clear demonstration during this period in 
Baltimore by D.E. Davis (1952) and his associates at the 
Johns Hopkins University School of Hygiene & Public Health 
that environmental improvement and sanitation could effec-
tively control outdoor rat populations, rodenticide use contin-
ued to be highly favored by those involved—residents and 
professionals alike. After all, dead rats were visible proof of 
efficacy, and forced environmental cleanup was not required. 
Environmental deficiencies could be over-ridden with a 
chemical “fix.” 
TOXICITY AND SAFETY 
Incredibly small amounts of technical Warfarin are re-
quired for effective control. PCOs were accustomed to using 
2% zinc phosphide baits, whereas anticoagulants are used at 
0.025% or 0.005%. It was difficult for PCOs to fully appreci-
ate the chemical characteristics of this new control tool. 
Such formulation use ratios, however, do not appropri-
ately represent relative toxicity. The LD50 statistic is utilized 
so that chemicals causing acute responses, such as zinc phos-
phide or 1080, could be compared readily. But when this 
statistic was determined for the anticoagulants as well, the 
potential for misuse was high. The acute (single) dose of 
Warfarin required to kill 50% of a test population of rats was 
calculated at around 200 mg/kg (Tables 1 and 2). This meant 
a massive dose was required to kill and that the compound 
would be regarded of low toxicity. 
But wait! That’s not how anticoagulants are used. War-
farin is fed to rats every day for a week. Then the animal dies 
from chronic (not acute) causes, such as internal bleeding. 
The secret is the small daily dose. With recalculation, the 
LD50 becomes about 2 mg/kg–0.3 mg/kg daily for a week 
(Table 2); but this then is a 5-day LD50 value (Ashton, Jack-
son and Peters 1986). 
Furthermore, considerable variation exists among spe-
cies and laboratory strains and between sexes. Generally, fe- 
Table 1. Oral LD50 values (mg/kg) for Norway rats.a 
Table 2. Acute oral LD50 doses (mg/kg) 
domestic Norway rat.a 
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males are less susceptible than males, wild rats are less sus-
ceptible than domestic (laboratory) rats, and house mice are 
considerably more tolerant than Norway rats (Table 3). In our 
tests, Pival toxicity for rats deviated considerably from that 
seen for other products. While anticoagulants generally are 
effective on rodents (and other mammals) worldwide, care 
must be exercised in assuming that Norway rat data “fit” all 
species. 
If just numbers are compared, Warfarin thus appears 
more toxic than Compound 1080 (LD50 = 5 mg/kg). It is the 
required 5-day sequential feeding period that minimizes haz-
ards with the use of first-generation anticoagulants. All too 
often in text books and other reference documents the antico-
agulant LD50 statistic is not labeled as a 5-day LD5o (or oth-
erwise distinguished from an acute LD50). In fact, the range 
often is given (e.g., 2-200 mg/kg), which further confuses 
interpretation. The World Health Organization included 
Warfarin in a table of technical products classified as “highly 
hazardous” along with such compounds as sodium cyanide, 
strychnine, and endrin (WHO 1988). The uninitiated jump to 
the wrong conclusion relative to hazard. Numerous unneces-
sary crises have occurred—especially relative to waste bait 
transport and disposal—that should have been avoided. 
This is not to say that first-generation anticoagulants are 
without use hazards. A predator feeding daily (or at least 
frequently) on rodents that have tissue residues or stomachs 
filled with toxic bait can be adversely affected. A single feed-
ing by a predator on the bait itself or on an affected target 
species will not impact the predator—just as a single feeding 
will not impact the target species. However, canids do seem 
more sensitive to diphacinone than other predators, and other 
species differences have been noted. 
Concern over the presence of anticoagulants in the hu-
man food chain, especially for pregnant women, prompted 
the Hawaiian sugar cane industry to discontinue use of these 
rodenticides in perimeter areas of Hawaiian sugar cane fields. 
The linkage was with wild pigs feeding on the bait place-
ments and then being hunted and killed for food (Engeman 
and Pank 1984). Because of this action, zinc phosphide re-
mains the only chemical tool for rodent control in sugar cane. 
Table 3. Daily dose (5-day) oral LD50 (mg/kg).a 
FORMULATIONS 
Initial formulations were grain mixtures (often corn and 
oats) with a bit of vegetable oil and sugar. In time pellets were 
created, some using heat processing, others with simple com-
pression. Wax formulations were developed, especially 
for humid environments. EPA prohibited loose baits in 
sewer systems due to threat of bait being flushed into water-
ways. Wax blocks could be restrained and were labeled for 
such uses. 
Always at hand was the conflict between marketing a 
universal rodent bait or designing distinctive formulations for 
rats and mice. Smaller formulators tended to follow the uni-
tary approach—but found the competition increasingly stiff. 
One distinct disadvantage of single products was the higher 
formulation concentration needed to kill mice, since their 
LD50 was four times that of rats. Other formulators were able 
to improve mouse acceptance (and presumably efficacy) with 
special mixtures of seeds and fine particles. 
Packaged baits (whether pellet or loose grain) had the 
advantage of being an activity measure. Until the package 
seal was broken, the dry contents remained intact and palat-
able. A broken package evidenced new rodent activity and 
was cause for the PCO to increase surveillance. 
Modifications then turned to solid bait configurations. 
The idea of designing baits with multiple gnawing edges to 
increase feeding caught on, but the difference between the 
dental apparatus of rats and mice had to be observed. Mice 
needed smaller ridges and pellet size. Some of these solid 
baits were designed to be quickly fastened in place to prevent 
their being dragged away. Attempts at innovation with tex-
ture and shape as well as with color (though rats are color 
blind), flavor and odor will continue. 
EPA early on established efficacy criteria that had to be 
met for product registration. For anticoagulants it was 90% 
mortality and 33% consumption of the toxic bait in a 15-day 
choice feeding test. 
This 33% consumption threshold has been maintained 
(except for wax block baits) despite test data indicating that 
90% mortality occurs above 25% of the intake being of toxic 
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bait in these laboratory tests (Palmateer and McCann 1976). 
When the second-generation anticoagulants came along, 
some semantic and procedural problems occurred. These 
compounds killed anticoagulant-resistant rats and mice. (Did 
rodents proved resistant to both coumarin and indandione 
compounds have to be used in such efficacy tests? Yes.) 
These compounds acted like acutes, killing after a single 
feeding—but still some days later. Should the 3-day test for 
acute toxicants be used? (No.) 
Recently EPA has proposed a 24-hour choice test for 
second-generation compounds that wish to make a single 
feeding claim (W. Jacobs, personal communication; OPP 
Designations 1.209 and 1.210, Revisions No. 10 and 9, 
respectively). We feel a 1-day feeding test should be no-
choice, since efficacy is not at issue—only whether a single 
day’s feeding provides a lethal does. Use of a 2-day choice 
feeding test to establish efficacy for these compounds seems 
superior to the 3-day (or 5-day) tests with an odd number of 
days that may result in position-biased test data. 
Initially, the concept of “throw” packs was prompted as 
a fast way of distributing a “safe” rodenticide in rat-infested 
areas. Gradually the term “place” pack has come into play, 
giving the idea that even anticoagulants need to be placed in 
burrows, protected areas, or bait stations. 
Bait stations, too, have been modified with some nudg-
ing from EPA. Hopefully, we are past trying to characterize 
bait stations with such absolute designations as “tamper-
proof and are looking at probability related “tamper-resis-
tant” criteria relative to material durability, compartment 
design, accessibility, stationability, and similar characteris-
tics. Baits should be placed in locations not easily attainable 
by children, pets, nontarget wildlife, or domestic animals. 
While rodenticides are widely used, their ingestion by 
nontarget species is very infrequent. For example, data from 
the National Poison Center Network (1978) indicated that 
only 0.63% of the more than 125,000 reported human expo-
sures to toxic substances involved rodenticides. 
Accidental poisoning of pets, similarly, is of concern. 
The Animal Poison Control Center (University of Illinois) 
logged more than 5,000 calls on its 24-hour hotline in 1982 
(Buck 1983). About half involved dogs. Only 8% of the total 
calls concerned anticoagulant rodenticides. Various 
household products, chemicals, medications, and plants were 
of far greater concern. 
Clearly rodenticides need to be used with care. Appro-
priate placement is essential. The pest control industry gener-
ally has demonstrated its ability to use these rodenti-
cides safely. 
RESISTANCE 
Anticoagulant resistance (to Warfarin) was first docu-
mented in Norway rats from a pig sty near Glasgow, Scotland 
by Mary Boyle in 1958 (Boyle 1960). Soon thereafter this 
phenomenon was identified in other areas of the U.K. and 
then on the continent. 
More than a decade later (1971) a North Carolina PCO 
reported that rats on his farm accounts were getting fat on 
Warfarin baits. Resistance had arrived in the U.S. (Jackson, 
Spear and Wright 1971; Jackson and Kaukeinen 1972). 
Even so, first-generation anticoagulants dominated the 
scene for PCOs, government programs, and householders. 
But inevitably, Warfarin resistance was determined to be 
cross-resistant, that is, resistance to Warfarin also was resis-
tance to the other first-generation (both coumarin and 
indandione) compounds. 
What Brought on Resistance? 
Anticoagulant resistance is inherited; it does not result 
from repeated exposures to low doses. In control programs 
with anticoagulants, rats that can eat the baits and survive 
(i.e., are resistant) have an evolutionary advantage: being 
parents of the next generation and passing resistant genes to 
at least some of their offspring. 
Warfarin resistance appears monogenic and dominant, 
being mediated by alterations in several vitamin K metaboliz-
ing enzymes that in turn reduce availability of blood clotting 
factors (MacNicoll 1986,1988). Although monogenic, many 
alleles may occur. For example, our Chicago (and other U.S.) 
strains appear less dependent on supplementary dietary vita-
min K than the Welsh strain and may be more like the Scot-
tish rats. However, virtually all the U.S. laboratory research 
has been done with the Welsh allele transferred into labora-
tory rats; and little attention has been paid to resistant wild 
Norway rats in the U.S. The relatively recent presence of 
difenacoum resistance in southern England provides support 
of the polygenic hypothesis for resistance to second-genera-
tion compounds (Greaves and Cullen-Ayres 1988). 
Interestingly, anticoagulant resistance in England was 
largely a rural phenomenon; in the U.S., largely urban. Why? 
The basic conditions that facilitate selection for resis-
tance appear to include abundant food, harborage, and persis-
tent (but perhaps inefficient) use of anticoagulant baits. In the 
U.K., government workers provided pest control services to 
farmers on a regular basis; in the U.S., it was urban govern-
ment sanitation workers and some PCOs that did so. 
My thesis is that the regular use of Warfarin (and other 
anticoagulant) baits killed off the susceptible rats (those with-
out the resistant gene). The breeding population by this selec-
tion process increased its proportion of resistant rats. Since 
the environmental conditions usually were not altered, many 
rats remained isolated from control efforts but were readily 
available for breeding—and the passing of the resistant gene. 
In the 1970s urban rat control became a politically cor-
rect activity, and some $15 million in federal funds were 
allocated annually to states and cities for urban rat control 
programs. This lasted for more than a decade. 
These efforts often facilitated the selection of resistant 
rats by frequent rodenticide applications and lack of insis-
tence on environmental improvements. Laboratories at Troy 
(NY) and Bowling Green (OH) were utilized to monitor the 
resistance problem, and through their joint efforts resistance 
in Norway rats and/or roof rats was identified in 50 cities 
(Jackson et al. 1985; Jackson and Ashton 1986). Chicago was 
perhaps the most famous with more than two-thirds of the 
populations in target areas being resistant (Ashton and Jack-
son 1979). 
It was evident from PCO reports that house mice also 
were being selected for resistance in control programs. How-
ever, the federal funds supporting the urban rat control pro-
grams could not be used for surveillance on mice. 
Consequently, our data are limited to a few sites (Ashton and 
Jackson 1984). However, our assumption that resistance of 
house mice to anticoagulants is widespread (as has been dem-
onstrated in Europe) is supported by service records of PCOs. 
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SECOND-GENERATION ANTICOAGULANTS 
Recognition that resistance was widespread as well as 
the expanding consumer markets provided stimuli for 
industry’s synthesis and development of additional antico-
agulant-type compounds which would be effective against 
resistant populations. These became known as second-gen-
eration anticoagulants (Marsh, Howard and Jackson 1980). 
In addition, they became characterized as single-feeding 
rodenticides — a single feeding could provide a lethal dose, 
but the animal would not stop feeding nor would it die until 
5+ days later with characteristic internal hemorrhages. 
This single-feeding characteristic allowed the introduc-
tion of “pulsed baiting” as a control strategy (Dubock 1982). 
This could be very useful for the PCO but often was not 
understood. Baits could be placed at intervals (weekly or 
otherwise) with the knowledge that those animals that fed 
would die; subsequent bait placements similarly would kill 
remaining animals. This strategy accounted for dominance 
and territorial behavior in affected populations as well as 
population shifts during control programs. Increased opera-
tional efficiency was enjoyed, and reduced quantities of toxic 
baits had to be positioned in the environment, since continu-
ous feeding during the baiting period no longer had to be 
guaranteed (as with the first-generation compounds). 
Veterinarians had to learn that accidental poisoning with 
the new second-generation compounds was not the same as 
with Warfarin. The half-life of these new compounds was 
several months rather than several weeks. While administra-
tion of vitamin K was still the indicated therapy and transfu-
sions might be required, continued monitoring—sometimes 
for weeks—of the animal was necessary (Batten 1985, 
DuValletal. 1989). 
In addition, proposed broadcast field uses posed some 
problems. While voles in orchards and plantations could be 
readily controlled with these compounds, avian predators 
feeding intensively in such treated areas could be adversely 
affected by the residues in the target rodents (Hegdal and 
Colvin 1988). The question was whether predator mortality, 
limited geographically to these specific crop sites, could be 
tolerated when the larger area predator population was not 
significantly impacted. So far none of these compounds has 
been registered for area use, which suggests the attitude of 
regulatory groups. Any efforts to counter such concerns re-
quire population rather than laboratory studies, large teams of 
skilled personnel, and extensive support—which have not 
been available in recent years for minor-use materials 
(Kaukeinen 1982). 
One striking benefit from these preliminary studies was 
documentation that barn owls selectively foraged for voles in 
distant grassland and marsh areas and did not feed on farm-
stead rodents, even though the owls themselves roosted and 
nested in barns and silos. Consequently, rodenticide control 
of rodents in and around farm buildings would not impact 
these owls (Hegdal, Colvin and Blaskiewicz 1984). This al-
lowed ICI to retain “in and around farm building” use instruc-
tions on their label, whereas other baits were restricted for use 
“within” farm buildings. 
THE FUTURE 
In 1990, 70 companies held registrations for 176 first-
generation formulations (technical and bait); ten companies 
had registered 49 second-generation formulations. However, 
the EPA reregistration process will exact its toll. Warfarin, 
chlorophacinone, and diphacinone likely will be the only first-
generation anticoagulant survivors. General label statements 
will restrict uses to in and around buildings. Continued use of 
chlorophacinone for winter vole control in orchards will be 
requested by LiphaTech. Expansions of other labels are un-
likely because of costs unless a realistic risk/benefit climate 
prevails. 
Bitrex as a bait additive to prevent (by its bitter taste) 
accidental ingestion, already in use by ICI and J.T. Eaton in 
some of their formulations, may have popular appeal. Encap-
sulation of the technical material, already tried without much 
success, probably will not be worth the cost for anticoagu-
lants in the future. Antibiotic additives (to inhibit manufac-
ture of vitamin K by bacteria in the gut) similarly have little 
support. 
Resistance, once established in a population, does not 
seem to decrease significantly with time, even when antico-
agulants no longer are employed. We established that high 
levels (67%) of first-generation anticoagulant resistance were 
present in the Chicago target areas in the mid-1970s. A de-
cade later we again tested animals from one of these popula-
tions and found about 85% resistant. (City workers and 
residents had been instructed not to use first-generation anti-
coagulants, but the ban may not have been wholly effective. 
Possibly the use of second-generation compounds maintained 
some selection pressure in the interim.) We don’t know if 
such experience is representative of other resistance sites in 
the U.S. 
Resistance already has been documented in the U.K. for 
bromadiolone and difenacoum (the latter not being available 
in the U.S.). Initial reports from Canada suggest broma-
diolone resistance there as well (Siddiqi and Blaine 1982), 
but no reports of resistant populations in the U.S. have sur-
faced. This may be simply a matter of not having looked 
carefully enough or conducted appropriate tests. So far, 
brodifacoum (Talon) has not been tarnished by reports of 
resistant populations anywhere in North America. 
New second-generation anticoagulants may emerge from 
the EPA labyrinth. Field testing for difethialone has been 
completed by LiphaTech (Lechevin and Poche, 1988). 
Flocoumafen is marketed in Europe but is not likely to see 
registration in the U.S. These are both similar to the existing 
second-generation compounds. Appropriate alternation of 
anticoagulants with non-anticoagulants by PCOs and sanitar-
ians will go a long way toward blocking the selection for 
populations resistant to second-generation compounds. 
Environmental uses for rodenticides will have increasing 
demands for orchards, no-till cropping schemes, and tropical 
row and tree crops. Uses of anticoagulants in these environ-
ments which minimize nontarget species hazard will require 
careful formulation, placement, and timing. Unfortunately, 
virtually no corporate resources are being dedicated to field 
research in support of such new registrations. 
Current rodenticides, especially the remaining antico-
agulants, will continue to have wide use because of their 
relative safety, efficacy, and general utility; but there are likely 
to be fewer allowable applications due to the high costs of 
data development. Agricultural needs (especially outside the 
continental U.S.) will increase. U.S. AID-related assistance, 
however, will have difficulty in participating because compa- 
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rable rodenticide uses (and labels) do not exist in the U.S., 
and foreign uses are thereby limited for AID programs. Ur-
ban demands everywhere will continue, especially in the ab-
sence of coordinated environmental sanitation programs (that 
is, integrated pest management). 
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